Trials / Unknown
UnknownNCT05368051
Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Beijing Friendship Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical research is to establish a multi-omics model based on genomics，transcriptomics，gut microbiota in predicting pathologic response after neoadjuvant chemoradiotherapy combined PD-1 antibody given to patients with locally advanced rectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | long course radiotherapy + capecitabine + PD-1 monoclonal antibody | long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer |
Timeline
- Start date
- 2021-10-01
- Primary completion
- 2022-10-31
- Completion
- 2022-10-31
- First posted
- 2022-05-10
- Last updated
- 2022-05-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05368051. Inclusion in this directory is not an endorsement.